{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:18:51Z","timestamp":1794277131332,"version":"4.9.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.reuma.2018.11.011","type":"journal-article","created":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T00:56:12Z","timestamp":1547859372000},"page":"195-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Enfermedad relacionada con IgG4: \u00bfes el rituximab la mejor estrategia terap\u00e9utica en los casos refractarios a terapia convencional? Resultados de una revisi\u00f3n sistem\u00e1tica"],"prefix":"10.1016","volume":"16","author":[{"given":"Laura","family":"Betancur-V\u00e1squez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gonzalez-Hurtado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Arango-Isaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Rojas-Villarraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deicy","family":"Hernandez-Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"D\u00edaz-Coronado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.reuma.2018.11.011_bib0245","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(14)60720-0","article-title":"IgG4-related disease","volume":"385","author":"Kamisawa","year":"2015","journal-title":"Lancet."},{"key":"10.1016\/j.reuma.2018.11.011_bib0250","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.reuma.2016.05.009","article-title":"Enfermedad relacionada con IgG4: revisi\u00f3n concisa de la literatura","volume":"13","author":"Ardila-Suarez","year":"2017","journal-title":"Reumatol Clin."},{"key":"10.1016\/j.reuma.2018.11.011_bib0255","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.medcli.2014.12.017","article-title":"Enfermedad relacionada con IgG4","volume":"145","author":"Gonz\u00e1lez-Moreno","year":"2015","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.reuma.2018.11.011_bib0260","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/TCRM.S99985","article-title":"IgG4-related disease: Current challenges and future prospects","volume":"12","author":"Lang","year":"2016","journal-title":"Ther Clin Risk Manag."},{"key":"10.1016\/j.reuma.2018.11.011_bib0265","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/s10165-011-0571-z","article-title":"Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011","volume":"22","author":"Umehara","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.reuma.2018.11.011_bib0270","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2214\/AJR.13.11247","article-title":"Recent advances in the diagnosis and management of autoimmune pancreatitis","volume":"202","author":"Khandelwal","year":"2014","journal-title":"AJR Am J Roentgenol."},{"key":"10.1016\/j.reuma.2018.11.011_bib0275","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/modpathol.2012.72","article-title":"Consensus statement on the pathology of IgG4-related disease","volume":"25","author":"Deshpande","year":"2012","journal-title":"Mod Pathol."},{"key":"10.1016\/j.reuma.2018.11.011_bib0280","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/14397595.2017.1290911","article-title":"Current approach to the diagnosis of IgG4-related disease\u2013Combination of comprehensive diagnostic and organ-specific criteria","volume":"27","author":"Umehara","year":"2017","journal-title":"Mod Rheumatol."},{"key":"10.1016\/j.reuma.2018.11.011_bib0285","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2007.12.009","article-title":"Immunoglobulin G4-associated cholangitis: Clinical profile and response to therapy","volume":"134","author":"Ghazale","year":"2008","journal-title":"Gastroenterology."},{"key":"10.1016\/j.reuma.2018.11.011_bib0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0000000000000680","article-title":"IgG4-related disease: Dataset of 235 consecutive patients","volume":"94","author":"Inoue","year":"2015","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.reuma.2018.11.011_bib0295","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1136\/gutjnl-2012-302886","article-title":"Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: The Mayo Clinic experience","volume":"62","author":"Hart","year":"2013","journal-title":"Gut."},{"key":"10.1016\/j.reuma.2018.11.011_bib0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","author":"Moher","year":"2009","journal-title":"PLoS Medicine."},{"key":"10.1016\/j.reuma.2018.11.011_bib0305","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/1752-1947-7-223","article-title":"The CARE guidelines: Consensus-based clinical case reporting guideline development","volume":"7","author":"Gagnier","year":"2013","journal-title":"J Med Case Rep."},{"key":"10.1016\/j.reuma.2018.11.011_bib0310","unstructured":"Critical Appraisal Skills, Programme., CASP., qualitative research, checklist. 2018."},{"key":"10.1016\/j.reuma.2018.11.011_bib0315","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0025-7753(05)72205-3","article-title":"Ensayos cl\u00ednicos aleatorizados (CONSORT)","volume":"125","author":"Cobos-Carb\u00f3","year":"2005","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.reuma.2018.11.011_bib0320","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/jamadermatol.2016.4854","article-title":"IgG4-related disease with orbital pseudotumors treated with rituximab combined with palpebral surgery","volume":"153","author":"Aouidad","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.reuma.2018.11.011_bib0325","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/acr.22058","article-title":"Usefulness of 2-[18 F]-fluoro-2-deoxy-d-glucose-positron emission tomography\/computed tomography for staging and evaluation of treatment response in IgG4-related disease: A retrospective multicenter study","volume":"66","author":"Ebbo","year":"2014","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.reuma.2018.11.011_bib0330","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/annrheumdis-2014-205233","article-title":"Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations","volume":"74","author":"Wallace","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2018.11.011_bib0335","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/annrheumdis-2014-206605","article-title":"Rituximab for IgG4-related disease: A prospective, open-label trial","volume":"74","author":"Carruthers","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2018.11.011_bib0340","doi-asserted-by":"crossref","unstructured":"Perugino CA, Wallace ZS, Meyersohn N, Oliveira G, Stone JR, Stone JH. Large vesselinvolvement by IgG4-related disease. Med (United States). 2016;95(28).","DOI":"10.1097\/MD.0000000000003344"},{"key":"10.1016\/j.reuma.2018.11.011_bib0345","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/art.39132","article-title":"International consensus guidance statement on the management and treatment of IgG4-related disease","volume":"67","author":"Khosroshahi","year":"2015","journal-title":"Arthritis Rheumatol [Internet]."},{"key":"10.1016\/j.reuma.2018.11.011_bib0350","doi-asserted-by":"crossref","first-page":"e4002","DOI":"10.1097\/MD.0000000000004002","article-title":"Therapeutic approach to IgG4-related disease","volume":"95","author":"Brito-Zer\u00f3n","year":"2016","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.reuma.2018.11.011_bib0355","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.semarthrit.2013.11.008","article-title":"Ophthalmic manifestations of IgG4-related disease: Single-center experience and literature review","volume":"43","author":"Wallace","year":"2014","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.reuma.2018.11.011_bib0360","first-page":"1000","article-title":"Predictors of disease relapse in IgG4-related disease following rituximab","volume":"55","author":"Wallace","year":"2016","journal-title":"Rheumatol (United Kingdom)."},{"key":"10.1016\/j.reuma.2018.11.011_bib0365","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MD.0b013e3182431ef6","article-title":"Rituximab for the treatment of IgG4-related disease: Lessons from 10 consecutive patients","volume":"91","author":"Khosroshahi","year":"2012","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.reuma.2018.11.011_bib0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0183844","article-title":"Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients","volume":"12","author":"Ebbo","year":"2017","journal-title":"PLoS One."},{"key":"10.1016\/j.reuma.2018.11.011_bib0375","doi-asserted-by":"crossref","first-page":"e6205","DOI":"10.1097\/MD.0000000000006205","article-title":"Ophthalmic manifestations in IgG4-related disease: Clinical presentation and response to treatment in a French case-series","volume":"96","author":"Ebbo","year":"2017","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.reuma.2018.11.011_bib0380","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/ejh.12842","article-title":"IgG4-related disease and lymphocyte-variant hypereosinophilic syndrome: A comparative case series","volume":"98","author":"Carruthers","year":"2016","journal-title":"Eur J Haematol."},{"key":"10.1016\/j.reuma.2018.11.011_bib0385","first-page":"2012","article-title":"Development of an IgG4-RD responder index","author":"Carruthers","year":"2012","journal-title":"Int J Rheumatol."},{"key":"10.1016\/j.reuma.2018.11.011_bib0390","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5414\/CN107037","article-title":"Membranous nephropathy: A rare renal manifestation of IgG4-related systemic disease","volume":"77","author":"Jindal","year":"2012","journal-title":"Clin Nephrol."},{"key":"10.1016\/j.reuma.2018.11.011_bib0395","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.survophthal.2011.07.004","article-title":"IgG4-related systemic disease as a cause of \u201cidiopathic\u201d orbital inflamation, including orbital myositis, and trigeminal nerve involvement","volume":"57","author":"Wallace","year":"2012","journal-title":"Surv Ophthalmol."},{"key":"10.1016\/j.reuma.2018.11.011_bib0400","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/ejh.12059","article-title":"IgG4-related disease with hypergammaglobulinemic hyperviscosity and retinopathy","volume":"90","author":"Wong","year":"2012","journal-title":"Eur J Haematol."},{"key":"10.1016\/j.reuma.2018.11.011_bib0405","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1097\/IOP.0b013e3182a64fa4","article-title":"Successful \u201cMedical\u201d orbital decompression with adjunctive rituximab for severe visual loss in IgG4-related orbital inflammatory disease with orbital myositis","volume":"30","author":"Chen","year":"2014","journal-title":"Ophthal Plast Reconstr Surg."},{"key":"10.1016\/j.reuma.2018.11.011_bib0410","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamaneurol.2014.40","article-title":"Central nervous system manifestation of IgG4-related disease","volume":"71","author":"Regev","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.reuma.2018.11.011_bib0415","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/ajd.12100","article-title":"IgG4-related disease with cutaneous manifestations treated with rituximab: Case report and literature review","volume":"55","author":"Jalilian","year":"2013","journal-title":"Australas J Dermatol."},{"key":"10.1016\/j.reuma.2018.11.011_bib0420","first-page":"549","article-title":"Successful treatment of IgG-4 related sclerosing disease with rituximab: A novel case report","volume":"33","author":"Gillispie","year":"2015","journal-title":"Clin Exp Rheumatol."},{"key":"10.1016\/j.reuma.2018.11.011_bib0425","doi-asserted-by":"crossref","first-page":"e1366","DOI":"10.1097\/MD.0000000000001366","article-title":"Rituximab for the treatment of IgG4-related tubulointerstitial nephritis","volume":"94","author":"McMahon","year":"2015","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.reuma.2018.11.011_bib0430","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3109\/01676830.2015.1057290","article-title":"Bilateral orbital IgG4-related disease with systemic and corneal involvement showing an excellent response to steroid and rituximab therapy: Report of a case with 11 years follow-up","volume":"34","author":"Berta","year":"2015","journal-title":"Orbit"},{"key":"10.1016\/j.reuma.2018.11.011_bib0435","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1007\/s10067-016-3292-z","article-title":"Myocardial ischemia as presenting manifestation of IgG4-related disease: A case-based review","volume":"35","author":"Delgado-Garc\u00eda","year":"2016","journal-title":"Clin Rheumatol."},{"key":"10.1016\/j.reuma.2018.11.011_bib0440","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jneuroim.2016.08.009","article-title":"Treatment of IgG4-related pachymeningitis in a patient with steroid intolerance: The role of early use of rituximab","volume":"299","author":"Gospodarev","year":"2016","journal-title":"J Neuroimmunol."},{"key":"10.1016\/j.reuma.2018.11.011_bib0445","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00795-016-0139-2","article-title":"IgG4-producing lymphoma arising in a patient with IgG4-related disease","volume":"49","author":"Igawa","year":"2016","journal-title":"Med Mol Morphol."},{"key":"10.1016\/j.reuma.2018.11.011_bib0450","doi-asserted-by":"crossref","first-page":"e4633","DOI":"10.1097\/MD.0000000000004633","article-title":"Antineutrophil cytoplasmic antibody positivity in IgG4-related disease","volume":"95","author":"Della-Torre","year":"2016","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.reuma.2018.11.011_bib0455","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006934","article-title":"Rituximab was used to treat recurrent IgG4-related hypophysitis with ophthalmopathy as the initial presentation: A case report and literature review","volume":"96","author":"Gu","year":"2017","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.reuma.2018.11.011_bib0460","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2169\/internalmedicine.56.8013","article-title":"Overlap of IgG4-related disease and multicentric Castleman's disease in a patient with skin lesions","volume":"56","author":"Mochizuki","year":"2017","journal-title":"Intern Med."},{"key":"10.1016\/j.reuma.2018.11.011_bib0465","first-page":"20","author":"Su","year":"2017","journal-title":"Concurrent IgG4-related tubulointerstitial nephritis and IgG4 myeloperoxidase-anti- neutrophil cytoplasmic antibody positive crescentic glomerulonephritis."},{"key":"10.1016\/j.reuma.2018.11.011_bib0470","doi-asserted-by":"crossref","unstructured":"Wu PC, Tien PT, Li YH, Chen RY, Cho DY. IgG4-related cerebral pseudotumor with perineural spreading along branches of the trigeminal nerves causing compressive optic neuropathy. Medicine (Baltimore). 2017; 96: 1-7.","DOI":"10.1097\/MD.0000000000008709"},{"key":"10.1016\/j.reuma.2018.11.011_bib0475","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/art.27435","article-title":"Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease","volume":"62","author":"Khosroshahi","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2018.11.011_bib0480","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/modpathol.2014.91","article-title":"Lymphoplasmacytic sclerosing pancreatitis without IgG4 tissue infiltration or serum IgG4 elevation: IgG4-related disease without IgG4","volume":"28","author":"Hart","year":"2014","journal-title":"Mod Pathol"}],"container-title":["Reumatolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X18302651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X18302651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:59:58Z","timestamp":1761663598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699258X18302651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S1699258X18302651"],"URL":"https:\/\/doi.org\/10.1016\/j.reuma.2018.11.011","relation":{},"ISSN":["1699-258X"],"issn-type":[{"value":"1699-258X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enfermedad relacionada con IgG4: \u00bfes el rituximab la mejor estrategia terap\u00e9utica en los casos refractarios a terapia convencional? Resultados de una revisi\u00f3n sistem\u00e1tica","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reuma.2018.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Reumatolog\u00eda y Colegio Mexicano de Reumatolog\u00eda. All rights reserved.","name":"copyright","label":"Copyright"}]}}